Possible Heart Risk With Testosterone Spurs Debate on Use

By Caroline Chen Sep 16, 2014 8:21 AM CT

Testosterone supplements used last year by about 2.3 million men are spurring debates over how necessary and safe they may be, even as U.S. regulators consider approving a new product.

Food and Drug Administration advisers tomorrow will consider whether the drugs are being prescribed to the right people. They also will weigh whether the labels should change to reflect heart risks suggested by some studies, according to FDA briefing documents.

The number of men taking testosterone supplements grew by 1 million between 2010 and last year, when AbbVie Inc.’s Androgel, the market leader, generated $1.04 billion in sales. At the same time, 21 percent of patients didn’t have evidence of laboratory testing before taking the supplements, according to an analysis of utilization data that the FDA staff called “particularly concerning” in its briefing document.

“We don’t expect there will be a major change in the labels for these drugs,” said Eric Schmidt, an analyst at Cowen & Co., in a telephone interview. “But if there were a major negative change to the prescribing materials, you could see a more substantial impact.”

While testosterone replacement therapy has been approved in the United States since 1950 for men with medical conditions leading to deficiencies, such as testicular damage due to chemotherapy, use has surged in men who have low testosterone for no other reason than age, the FDA document said.

Top Sellers

Other sellers of testosterone products include Indianapolis-based Eli Lilly & Co. (LLY), which had $179 million in sales last year for its treatment, called Axiron; and Auxilium Pharmaceuticals Inc. (AUXL), which gained $271 million in 2013 for its Testim gel and Testopel, testosterone pellets implanted under the skin.

The newest product is Rextoro, made by closely-held Clarus Therapeutics Inc. The company is seeking approval for what would be the first oral testosterone medicine in 50 years, according to the drugmaker. The FDA advisers will consider the product on Thursday.

An FDA staff report on Rextoro released today questioned whether efficacy and safety data provided by Northbrook, Illinois-based Clarus are adequate given the company’s key final-stage trial was missing data on 19 percent of participants after about four months of therapy.

Uncertain Conclusions

FDA staff also said they couldn’t draw definitive conclusions on potential cardiovascular risk associated with the drug. The agency is asking the panel to discuss whether more safety studies are needed and whether they should be conducted before or after approval.

“We are looking forward to participating in the FDA Advisory Committee meeting,” said Keri Mattox, a spokeswoman for Auxilium, in an e-mail. “Next steps for the industry will depend upon the outcome of the meeting.”

“It’s premature to speculate on the impact at this juncture,” said Celeste Stanley, an Lilly spokeswoman, in a telephone interview. AbbVie spokeswoman Libby Holman declined to discuss the possible outcomes of the FDA meeting.

So far, data on the drugs’ cardiovascular effects have been limited and conflicting, the FDA said.

November Study

A November study of more than 8,000 men found that testosterone replacement drugs boosted the odds of a heart attack, stroke, or dying by 29 percent. Two other studies, in contrast, found a significant reduction in overall mortality associated with testosterone therapies.

The FDA’s position is “benign” and the agency is unlikely to restrict use, wrote analyst Michael Yee in a Sept. 4 note to clients. Yee said the panel is considering asking drugmakers to run post-marketing cardiovascular studies, which “does seem a bit unreasonable” for smaller biotechnology firms such as Auxilium.

Ultimately, the agency is “unlikely to say something that will completely clear the air here,” Schmidt said. “There may be some overhang in the stock price for a worse case scenario, so we may see a bit of a relief rally if the FDA does nothing.”

To contact the reporter on this story: Caroline Chen in New York at cchen509@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Drew Armstrong

Related Posts

Leave a Reply

Recent Articles

Status of Baby Formula Lawsuits
May 25, 2022
Mardi Gras Road Safety Tips
Mardi Gras Road Safety Tips
February 9, 2022
Practice Road Safety this Holiday Season
Holiday Distracted Driving: Practice Road Safety this Season
December 14, 2021
Jordan Davis
Jordan Davis
13:24 20 Aug 19
Love the whole legal team at Taylor Martino. They truly care about their clients. Would not go to any another Injury... Lawyer in Alabama!read more
Kiyyah Malik
Kiyyah Malik
19:09 13 Jun 19
Ben Kearns and the staff at Taylor Martino made a terrible situation (car accident) into a much simpler less stressful... process. I appreciate all the dedication and hard work. They are highly recommended in my book!read more
Shadow Yuuki
Shadow Yuuki
20:04 22 May 19
These guys are the best. If anyone needs a lawyer, they did what they said they where going to do and when they said... they going to do it i got everything i should have. They are the best lawyers in Mobileread more
21:34 20 May 19
I heard about Ed Rowan from my aunt and gave him a call. Ed Rowan got things done in a timely matter and Elizabeth... Wright was very helpful and quick to respond when I had any questions.read more
Tim Howard
Tim Howard
15:11 23 Sep 18
I highly recommend the firm as they took my case and settled it quickly. They took me in and treated me like family... from day one. They kept me informed throughout the process and never left me feeling uncomfortable. Ben and Jennifer went above and beyond what anyone would expect.read more
sree harsha sunkara
sree harsha sunkara
15:14 13 Apr 18
This was the best law firm I have ever experienced. All I did was just contacted them and they did the rest for me and... updated me every week about the work in process. They were so good and I highly recommend them in case of any accidentsread more
Next Reviews